MM&M’s Top 100 North American healthcare agencies of 2022
We are happy to announce that PRECISIONvalue and PRECISIONeffect have made the list of MM&M’s Top 100 North American healthcare agencies of 2022!
We are happy to announce that PRECISIONvalue and PRECISIONeffect have made the list of MM&M’s Top 100 North American healthcare agencies of 2022!
Each year, Med Ad News honors the best in healthcare communications and advertising through the Manny Awards. This year, we are excited to announce that PRECISIONvalue has been selected as a 2022 Manny Awards finalist in the Best Managed Markets Campaign Category for “Overcoming Hurdles”.
Recent acquisition of veteran pharmaceutical market consultancy Oncology Reimbursement Management propels and further elevates Precision’s oncology commercialization solutions.
In 2021, NCQA and HL7 hosted the fifth annual Digital Quality Summit (DQS) that convened stakeholders within six distinct “tracks” – each track exploring a different subset of healthcare. PRECISIONvalue’s Dominic Galante, MD, Jorge Font, MPH, and Maureen Hennessey, PhD, provided consultation to the Helmsley Charitable Trust, sponsors of the Track 6 “Rethinking Diabetes Care in the Digital Age.” Dr. Hennessey and Michael Barr, MD, of NCQA served as track co-leaders.
Boston – August 3, 2021 – PRECISIONeffect, the industry’s only healthcare advertising agency dedicated to changing the standard of care, today announced that it has acquired Pascāle, an international healthcare communications company specializing in public relations and social media. Pascāle has an almost two-decade history of launching full-scale, creative-fueled PR and social media campaigns to drive results for healthcare clients worldwide.
Addition of a Key Access Stakeholder Will Provide Clients With Winning Strategies to Address Complex and Rapidly Changing Cost and Utilization Challenges
APRIL 14, 2021 – New York, NY – PRECISIONvalue, a Precision Value & Health team, today announced the further strategic expansion of its Access Experience Team (AET), a specialized group of former access decision markers, with the addition of Christy Banach. Christy’s deep oncology practice background bolsters Precison’s ability to futher drive strategic and implementation support related to real-time experiences being managed at the point of patient care within oncology practices. (more…)
EU-based team brings a unique omnichannel optimization platform and digital transformation capabilities to leading life-sciences companies
BETHESDA, MD—March 24, 2021—Precision Value & Health, the industry leader for commercialization services for innovative life science companies, today announced that it has acquired Across Health. Across Health is a leading global omnichannel engagement consultancy focused on providing clients an analytical and evidence-based framework for commercial strategy, execution, and resource optimization. The company’s solutions are based around its proprietary, market-leading Navigator365 product suite, which more than 40 pharmaceutical companies rely on for omnichannel planning and resource allocation. The Across Health team is already working hand-in-hand with Precision’s medical communications, creative, and data sciences teams to offer analytically driven launch and commercialization programs across the product life cycle.
Bethesda, Maryland and San Francisco, California—February 2, 2021—PRECISIONxtract and Datavant announced a market-shifting partnership where Precision will leverage the power of Datavant’s technology to support life science partners to better visualize and navigate the patient journey. Given PRECISIONxtract’s track record as a pioneer in data management solutions, multistakeholder analytics, and dynamic customer engagement combined with Datavant’s leadership to support healthcare organizations in safely connecting their data, this partnership will enable clients to deepen their visibility into the patient experience and solve key commercialization challenges that new therapies face.
LEADING BIO-ENGINEERING AND MANUFACTURING SERVICES FIRM CATALYZES THE LAUNCH OF PRECISION’S CELL AND GENE THERAPY OFFERING—’PRECISION ADVANCE’—ADDRESSING THE UNIQUE CHALLENGES OF CELL & GENE THERAPY INNOVATORS, FROM DEVELOPMENT THROUGH COMMERCIALIZATION
BETHESDA, MD—January 14, 2021—Precision Medicine Group (“PMG”) announced today it has acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies. Project Farma provides Precision a market-leading expertise in the manufacturing of life-changing medicines, with a unique focus in the rapidly growing area of cell and gene therapy. The acquisition adds Project Farma’s unique expertise to Precision’s suite of end-to-end cell and gene therapy capabilities to support development and commercialization.
PRECISION OFFERS LIFE SCIENCE CLIENTS DEEPER CONNECTIONS TO HCPs THROUGH LAUNCH OF ADVANCED TECHNOLOGY-DRIVEN PRODUCT LINES, EHR CONNECT™ AND ACCESS GENIUS™